The GLP-1 Market (Ozempic, Wegovy, Mounjaro, Zepbound)
Blockbuster obesity and diabetes drugs at the centre of fights over price, compounding and safety
GLP-1 drugs such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have transformed treatment of type 2 diabetes and obesity and become some of the best-selling medicines in history. They have also generated controversy over US prices far above those abroad, a boom and bust in compounded copies, government pricing deals, rival false advertising claims and differences between US and European safety warnings.
Questions
What are GLP-1 drugs and why are they so important?
GLP-1 agonists mimic a gut satiety hormone — Wegovy produced 18.8% average weight loss in 72 weeks — with Novo near $50 billion from Ozempic and Wegovy by 2024 and Zepbound at $4 billion in a single quarter in early 2026.
GLP-1 stands for glucagon-like peptide-1, a hormone produced in the gut that signals fullness and helps regulate blood sugar. GLP-1 drugs mimic this hormone. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are the leading products, used for diabetes and obesity. High-dose Wegovy produced average weight loss of about 18.8% in a 72-week trial. Demand has been enormous: Novo had made nearly $50 billion from Ozempic and Wegovy by 2024, and Zepbound recorded $4 billion in sales in a single quarter in early 2026. Epidemiologists cited by Senator Sanders estimated that more than 40,000 lives a year could be saved if weight-loss drugs were affordable and widely available. Their scale means pricing decisions for these drugs have major consequences for Medicare, employers and household budgets.
Q2How do US GLP-1 prices compare internationally?
Senator Sanders noted Ozempic was $969/month in the US vs $59 in Germany, and Wegovy $1,349 vs $92 in the UK — with a Yale study estimating the drugs could be profitably manufactured for under $5 a month.
US list prices are many times higher. At a September 2024 Senate HELP Committee hearing, Senator Bernie Sanders noted Novo Nordisk charged $969 a month for Ozempic in the US, compared with $155 in Canada, $122 in Denmark, $71 in France and $59 in Germany, and $1,349 a month for Wegovy versus $92 in the UK. Lilly's Zepbound and Novo's Wegovy had wholesale prices around $1,000 a month. Sanders cited a Yale study estimating the drugs could be profitably manufactured for less than $5 a month. He argued that if half of US adults took them, the cost could reach $411 billion a year. Novo's CEO said it has little control over what patients pay, pointing to insurers and PBMs.
Q3Why did compounded GLP-1s become so widespread?
A drug shortage listing let compounders sell semaglutide for $150–300/month vs $1,000+ branded — at the 2024 peak, nearly 1 in 3 Americans taking a GLP-1 got it from a compounder — creating an unregulated parallel market critics blame on high branded prices.
Under federal law, compounding pharmacies can make copies of drugs listed as in shortage. Surging demand put semaglutide and tirzepatide on the FDA's shortage list from 2022, and compounders sold versions at roughly $150 to $300 a month versus more than $1,000 for branded products. At the 2024 peak, nearly one in three Americans taking a GLP-1 said they got it from a compounder. Doctors raised safety concerns, because compounded versions lack FDA approval and some contain additional ingredients or different chemical forms. For many patients without insurance coverage for obesity, however, compounded drugs were the only affordable option. Critics argue that high branded prices created the conditions for this unregulated market.
Q4How has the FDA shut down GLP-1 compounding?
The FDA declared the semaglutide shortage resolved on February 21, 2025, then set wind-down deadlines — withstanding compounders' court challenges — and in September 2026 proposed to permanently bar semaglutide, tirzepatide and liraglutide from large-scale outsourcing facilities.
The FDA declared the semaglutide shortage resolved on February 21, 2025, having earlier done the same for tirzepatide, and set wind-down deadlines. The compounding industry sued, arguing the decision was flawed; a court denied preliminary injunctions and the FDA ended enforcement discretion for both drugs. In March 2026, a Fifth Circuit panel spent over an hour questioning whether the FDA followed the right procedure and looked at the facts fairly. In September 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would permanently bar large-scale outsourcing facilities from compounding them. Supporters say this protects patient safety; critics say it protects manufacturers' pricing.
Q5How have Lilly and Novo fought compounders?
Lilly sued Seattle clinics promoting a 'Seattle Zepbound Weight Loss Program' dispensing compounded tirzepatide; Novo sued for false equivalence to Ozempic and Wegovy — while also launching $499/month direct Wegovy and $349 Zepbound cash-pay programmes.
Both companies have sued. In June 2024 Lilly sued Seattle-area clinics and physicians, alleging they offered compounded tirzepatide while using Mounjaro and Zepbound trademarks, including promoting a "Seattle Zepbound Weight Loss Program" that did not dispense real Zepbound. A court allowed Lilly's false advertising claim to proceed, with trial scheduled for March 2026. Novo Nordisk's suits alleged that compounders marketed products as equivalent to Ozempic and Wegovy, claims the FDA has said are false and misleading. The companies argue compounded products are unapproved, unstudied and potentially unsafe. Compounders and some patient advocates argue the manufacturers are using litigation to eliminate lower-cost competition. Both firms have also launched direct-to-consumer cash-pay programmes, such as $499 a month for Wegovy and from $349 for Zepbound.
Q6What deals did the Trump administration strike on GLP-1 prices?
November 2025 deals with Lilly and Novo tied Medicare/Medicaid prices to the lowest abroad at $245/month, opened obesity coverage with $50 copays, and reportedly gave manufacturers a three-year tariff exemption — but pharmacy groups questioned how headline discounts compare with plans' existing net prices.
In November 2025 President Trump announced agreements with Lilly and Novo tying prices to the lowest paid abroad. Under the deals, Medicare and Medicaid prices for Ozempic, Wegovy, Mounjaro and Zepbound would be $245 a month, Medicare would cover Wegovy and Zepbound for obesity with related conditions for the first time, and beneficiaries would pay $50 copays. Cash prices on the new TrumpRx.gov site would start at $350 a month and trend down to $245 over two years, with oral versions priced lower. The companies reportedly received a three-year tariff exemption. Earlier, in April 2025, the administration had declined to finalise a Biden-era rule for Medicare obesity-drug coverage. Pharmacy groups noted it was unclear how headline discounts compare with net prices plans already pay.
Q7What is the false advertising fight between Novo and Lilly?
Novo sued Lilly on July 21, 2026 alleging ads compare Zepbound with 1.7 and 2.4mg Wegovy while concealing the 7.2mg dose approved in March 2026 — Lilly says it relies on SURMOUNT-5 data showing 47% less weight loss on 2.4mg Wegovy.
As Lilly overtook Novo in the obesity market, Novo sued Lilly on July 21, 2026 in New Jersey federal court under the Lanham Act. Novo alleges Lilly's ads for Zepbound and Mounjaro compare Lilly's highest doses with lower doses of Wegovy (1.7mg and 2.4mg) while omitting the 7.2mg Wegovy dose approved in March 2026, and that "Lilly knowingly cites outdated clinical trials." Novo says the ads have generated about 700 million impressions and it planned to seek a preliminary injunction. Lilly says its ads rest on SURMOUNT-5, which showed 2.4mg Wegovy produced 47% less relative weight loss than Zepbound, and notes Novo has never tested its highest doses head-to-head. The case shows how comparative claims have replaced supply as the main competitive battleground.
Q8What is the NAION safety controversy?
The EMA concluded in June 2025 that NAION — sudden, usually permanent vision loss — is a very rare semaglutide side effect with a ~2x increased risk in type 2 diabetes, yet US labels for Ozempic, Wegovy and Rybelsus still carried no NAION warning as of August 2026.
In June 2025 the European Medicines Agency's safety committee concluded that NAION, an eye condition that can cause sudden, usually permanent vision loss, is a very rare side effect of semaglutide, affecting up to 1 in 10,000 users, and that studies suggest about a two-fold increased risk in people with type 2 diabetes. It recommended stopping treatment if NAION is confirmed. The WHO issued a medical product alert later that month. A US plaintiff firm reports that as of August 2026, US labels for Ozempic, Wegovy and Rybelsus still contained no NAION warning, and that product liability lawsuits cite this gap, with bellwether trials expected late 2026 or 2027. Novo maintains that semaglutide's benefits outweigh its risks.
Q9How long will branded GLP-1s be protected from generics?
Generic semaglutide won't reach the US until at least 2032; tirzepatide's patents don't begin expiring until 2036 — contrast India, where Novo's semaglutide patent expired in March 2026 and Dr Reddy's won approval to sell generic semaglutide there.
A long time, by US standards. According to Stanford Medicine, generic semaglutide will not be available in the US until at least 2032, when Novo's first main patent expires, and Lilly's tirzepatide patents do not begin to expire until 2036. This contrasts with other markets: Novo's semaglutide patent in India expired in March 2026, and Indian manufacturer Dr Reddy's won approval to sell generic semaglutide there. Sandoz has also challenged a key semaglutide patent in Europe. The long US exclusivity window means that, absent negotiation or voluntary price cuts, American patients and payers will continue to pay branded prices for most of the next decade. This is why the pricing deals and Medicare negotiation matter so much.
Q10Why hasn't Medicare traditionally covered obesity drugs?
A statutory exclusion barred anti-obesity medications for weight loss — the CBO estimated adding coverage would cost ~$35 billion from 2026–2034 — and the Trump administration declined to finalise a Biden-era rule before the November 2025 deals created a $245/month obesity coverage route.
Medicare has not covered anti-obesity medications prescribed for weight loss, although it covers GLP-1s for other approved uses: it already covered Ozempic and Wegovy for diabetes and cardiovascular risk, and Zepbound for sleep apnoea. In November 2024 the Biden administration proposed extending Medicare and Medicaid coverage to obesity drugs, and the Congressional Budget Office estimated coverage would cost about $35 billion from 2026 to 2034, based on average annual costs of $5,600 per patient falling to $4,300. In April 2025 the Trump administration said it would not finalise that rule. About 12.5 million Medicare enrollees would qualify for anti-obesity medications in 2026, according to the CBO. The November 2025 deals then created a route to Medicare coverage for obesity at a $245 negotiated price and $50 copay. How this coverage is implemented and funded will shape the market's next phase.
Q11Why is the GLP-1 market likely to remain controversial?
Only 22% of commercial insurers cover GLP-1s for obesity; Florida's lawsuit extends the insulin rebate theory to Ozempic; Trulicity enters Medicare negotiation effective 2028; and unresolved compounding, advertising and NAION litigation make GLP-1s the new centre of the drug pricing debate.
Because the stakes are enormous. Obesity affects a large share of US adults, and coverage decisions could add tens of billions to Medicare costs; the CBO estimated that Medicare obesity-drug coverage would cost about $35 billion from 2026 to 2034. Only 22% of commercial insurers cover GLP-1s for obesity, leaving many to pay cash. Florida's September 2026 lawsuit extends the insulin rebate theory to GLP-1 drugs including Ozempic and Trulicity, and Trulicity was selected for Medicare price negotiation effective 2028. Add unresolved compounding litigation, the Novo-Lilly advertising fight and NAION litigation, and GLP-1s look set to replace insulin as the central battleground over drug pricing and access in the US.